



Zocere, Inc.

GENERATION NEXT IN STROKE THERAPEUTICS

Wayne Laslie
President & CEO



Every 40 seconds someone in the US has a stroke.

- Each year, about 795,000 people in the US suffer a stroke; 130,000 die
- Leading cause of long-term disability in adults
- The second most common cause of death worldwide
- \$73.7 billion in direct/indirect costs in US in 2010





The Problem

TIME IS OF THE ESSENCE

- **Neuronal damage associated with:**
 - **Deprivation of oxygen to the brain**
 - **Rapid reperfusion**
- **Passage of time-**
 - **Leads to permanent neurological damage, that**
 - **Leads to permanent disability or death**
- **Neuronal protection badly needed**





The Clot Busters

MORE PASSAGE OF TIME

Pharmacologic Agent to Dissolve Clots

- Activase[®] (tPA)

Devices to Break Up Clots

- MERCI Retrieval System and Penumbra System
 - Surgical procedure





What if we could

PROTECT THE BRAIN

from stroke-induced damage?





Zocere Solution: A Neuroprotectant Stroke Drug



- Novel peptide sequence derived from the brain-specific Striatal Enriched Protein (STEP) tyrosine phosphatase
- Natural STEP is a downstream regulator of a pathway for neuronal injury but degrades rapidly
- **STEP peptide** resists degradation, binds to and prevents p38 MAPK-dependant cell death
- Proof of Principle: Shown to reduce ischemic brain damage in animal models



Zocere, Inc.



Post-ischemic treatment with STEP peptide protects against ischemic brain damage



- Rats were subjected to right middle cerebral artery occlusion for 90 min followed by reperfusion (22.5 hr)
- **50% reduction** in total infarct volume observed

17814 • The Journal of Neuroscience, November 6, 2013 • 33(45):17814–17826

Neuroprotective Role of a Brain-Enriched Tyrosine Phosphatase, STEP, in Focal Cerebral Ischemia

Ishani Deb,^{1*} Namratta Manhas,^{1*} Ranjana Poddar,¹ Sathyanarayanan Rajagopal,¹ Andrea M. Allan,² Paul J. Lombroso,³ Gary A. Rosenberg,¹ Eduardo Candelario-Jalil,^{1,4} and Surojit Paul^{1,2}

Departments of ¹Neurology and ²Neurosciences, University of New Mexico Health Sciences Center, University of New Mexico, Albuquerque, New Mexico 87131, ³Yale University School of Medicine, Child Study Center, New Haven, Connecticut 06519, and ⁴Department of Neuroscience, University of Florida, Gainesville, Florida 32610



Zocere, Inc.



What Our STEP-Derived Peptide Does

Attenuates brain damage post ischemic insult and at reperfusion

- Administered via IV
- Crosses blood-brain barrier
- Resists degradation
- Use with any clot buster
- Eliminates need to diagnose stroke type before dosing





GOAL: IMMEDIATE STROKE THERAPY

No MRI | No neurosurgeon | No waiting





Capital Raised to Date

- **~\$500,000 raised from angel investors**
 - **Established an IP position. Retain global rights**
 - **Prepared a pre-clinical development plan to get to IND**
 - **Established a methodology for and prepared high levels of the peptide with a well-known FDA approved manufacturer**






What We Now Need To Make It Happen

Seeking \$5 million with initial \$1.5M tranche

- Continued validation of the peptide and initiate preclinical development leading to an IND



- **Exit Strategy: IND path**
 - **63 companies in last 3 years exited on path to IND**



Zocere, Inc.



Zocere Has The Leadership Team To Take Us There

Wayne Laslie, President and Chief Executive Officer

- 30+ years in pharmaceutical commercialization experience
- Former COO, Myriad Genetics & Myrexis

Kenton Zavitz, PhD, Chief Science Officer

- Drug development for Alzheimer's, HIV, oncology, acute pain
- Director, Myriad Genetics & Myrexis

Alan Kolod, Chief Financial Officer

- 30+ years in financial management and growing companies
- Former CFO, Future Medical Systems Group (Switzerland)



Zocere, Inc.



Let's Talk

Please direct inquiries to:

Wayne Laslie

575.737.8365

wlaslie@zocere.com

Alan Kolod

575.737.8364

akolod@zocere.com





Zocere, Inc.

GENERATION NEXT IN STROKE THERAPEUTICS